Swedish Orphan Biovitrum AB Reports Robust Q3 2026 Performance and Revisions to Full‑Year Outlook

Swedish Orphan Biovitrum AB (SOBI) delivered a markedly stronger third‑quarter 2026 result than market expectations, with revenue up 16 % at constant exchange rates and a 45 % adjusted EBITA margin, a clear sign that its portfolio of orphan‑drug therapies is gaining traction. The company’s CEO, Guido Oelkers, announced he will step down by the end of January 2027, paving the way for new leadership as the firm accelerates its global expansion.

Revenue Drivers

  • Total revenue rose to SEK 9.12 bn (previously SEK 7.78 bn), driven by a 29 % increase in haematology sales. The haematology segment benefited from strong performance of Altuvoct (SEK 1.73 bn) and Doptelet (SEK 1.83 bn).
  • Immunology revenue declined 6 % to SEK 2.53 bn. The dip was largely due to lower quarterly royalty receipts from Beyfortus (SEK 732 m) but was partially offset by solid sales of Gamifant (SEK 834 m) and Kineret (SEK 959 m).
  • The strategic portfolio grew 25 % at CER, reaching SEK 6.30 bn, underscoring the company’s ability to leverage its pipeline beyond core therapeutic areas.

Profitability and Cash Flow

  • Adjusted EBITA: SEK 3.99 bn, translating to a 45 % margin, a slight improvement over the 47 % reported last quarter.
  • EBITA: SEK 3.23 bn, reflecting an EBIT of SEK 3.23 bn after accounting for one‑off items.
  • Earnings per share (EPS): Adjusted EPS before dilution stood at SEK 6.96, up from SEK 6.11 a year earlier, while diluted EPS was SEK 6.89 versus SEK 6.05 previous year.
  • Operating cash flow: SEK 1.87 bn, a modest increase from the prior quarter, providing a cushion for continued R&D investment and potential capital deployment.

Forward‑Looking Guidance

SOBI has revised its 2026 revenue outlook to a high‑teens to low‑20s % growth at constant exchange rates, a modest lift from the previously forecast mid‑ to high‑teens percentage. The company maintains its adjusted EBITA margin target in the mid‑ to high‑30s % range, indicating confidence in sustained profitability.

The firm also reported a positive CHMP opinion for Tryngolza—its treatment for severe hypertriglyceridaemia (sHTG)—in Europe, a development that could unlock new revenue streams and diversify its product pipeline.

Market Reaction

Following the announcement, the stock advanced 2.9 % on the Swedish Stock Exchange, reflecting investor confidence in the company’s earnings rebound and the strategic trajectory of its pipeline. Analysts note that the sharp rise in EPS and robust margin expansion position SOBI favorably against peers in the rare‑disease biopharma space.

Conclusion

Swedish Orphan Biovitrum’s latest quarter underscores its resilience in a challenging therapeutic landscape. With a diversified portfolio, a solid cash position, and an upward‑revised revenue outlook, the company is poised to continue driving value for shareholders while advancing breakthrough treatments for rare and debilitating diseases worldwide.